Search

Living donor kidney transplantation is the preferred therapeutic option for patients with end stage renal disease because it provides a superior immunological compatibility, it lessens the preservation-mediated graft injury and it shortens waiting time on dialysis. Unfortunately, about 30-35% of potential living kidney donors are rejected because of incompatible immunological barriers such as ABO-incompatibility or a positive crossmatch. The newest desensitization protocols based on both therapeutic apheresis and perioperative immunosuppressive drugs allowed to overcome antibodies barriers. The aim of those protocols is to wash-out and suppress as much anti-A or anti-B antibodies as possible and to prevent the rebound phenomena after transplantation. Standard plasmapheresis, double-filtration plasmapheresis and selective immunoadsorption are among the most common apheretic modalities applied in ABO-incompatible transplantation. Furthermore, selective immunoadsorption appears to be much safer and to have markedly increased efficacy comparing with plasmapheresis being able to eliminate almost exclusively blood-group antibodies avoiding plasma and coagulation abnormalities. According to literature, long-term patient and graft survival rates are similar to those achieved by ABO-compatible kidney transplants. The comparable outcome seems related to more effective desensitization protocols as well as the protective immune mechanisms of "accommodation". We have been using selective immunoadsorption in the two ABO-incompatible kidney transplants performed in our institution. No acute rejection was experienced at 6 and 26 month follow-up and both grafts are functioning well. Despite the ABO-incompatible kidney transplant widespread use, the best desensitization protocol, the upper baseline and perioperative isoagglutinin titer limit and the most accurate isoagglutinin measurement assay are still to define.

Introduction: Laparoscopic living donor nephrectomy (LLDN) is supposed to be safe and effective and it ensures an excellent allograft function in the recipient. The use of laparoscopic technique is rapidly spreading in most transplant programs since it offers advantages over the open procedure. Aim of our study is to evaluate both surgical outcome and post-operative course in the LLDN group comparing with an historical series of open donor nephrectomies (ODN)., Materials and Methods: From January 1992 to August 2008, 37 living donor nephrectomies were performed in our center. 23 nephrectomies were carried out, laparoscopically and 14 by open technique. Donors characteristics were comparable in both groups., Results: All laparoscopic nephrectomies were performed successfully without conversion. No significant differences were observed between the two groups for both surgical complication and graft and patient survival rates. Mean warm ischemia time (p < 0.04), resumption of oral intake (p < 0.03) and length of hospital stay (p < 0.0001) were shorter in the LLDN group. Mean operative time (p < 0.036) was longer in the LLDN group, whereas time to return to work and daily activities were similar (p < 0.52)., Conclusion: Laparoscopic nephrectomy provides some post-operative advantages over the open technique without additional surgical risk ensuring comparable graft and patient outcomes. Therefore, LLDN has become the standard approach in our transplant center. However, the laparoscopic procedure should be performed only by experienced surgical staff in order to prevent serious complications in the donors.

We report the case of a patients with a metachronous cystic pancreatic metastasis from an undifferentiated large cell lung carcinoma two years after the primary tumor had been surgically removed. Clinically, he presented with epigastric pain, fever, weakness and anorexia. The patient was operated and a palliative cystogastrostomy was performed after an intraoperative biopsy had been informed as positive for carcinoma. Six months later the patient died. Pancreatic metastases from lung carcinoma are found in approximately 7-9% of patients deceased of this neoplasm. Clinical and radiological findings simulate primary pancreatic tumors, being epigastric pain, jaundice and upper digestive bleeding the most frequent symptoms. They represent stages of advanced systemic disseminated tumoral disease, and because of this reason total or partial surgical curative resections will only be performed in a few cases of patients with isolated metastasis, criteria of resectability and without evidence of extended disease to other organs or systems. In the most of the cases, the treatment will only be palliative, even medical or surgical.